Furthermore, the difference in SERPINA3 expression levels between the two groups, and its ability to serve as a marker gene to distinguish the cardiomyopathy group from the control group, was significantly greater than that of CD14 and CCL2. Thus, these merits further investigation into the diagnostic and therapeutic potential of SERPINA3 in cardiomyopathy. This evidence concerns the gene CD14 and cardiomyopathy.